Association between adherence to evidence-based guidelines for the prescription of non-steroidal anti-inflammatory drugs and the incidence of gastric mucosal lesions in Japanese patients
- First Online:
- 137 Downloads
Recently, guidelines for the treatment and prevention of ulcers induced by non-steroidal anti-inflammatory drugs (NSAIDs) were established. This study investigated the association between the current adherence to the guidelines and the incidence of gastric mucosal lesions caused by NSAIDs.
This study included 254 NSAIDs users (128 regular and 126 on-demand users) who had undergone upper gastrointestinal endoscopy. The patients were characterized as high risk based on the following: age 65 years or older, history of peptic ulcers, concurrent use of corticosteroids or anticoagulants, and high-dose NSAIDs use. Adherence was defined as the prescription of NSAIDs with proton pump inhibitors, prostaglandin analogues, or high-dose histamine 2 receptor antagonists in high-risk NSAIDs user. The severity of gastric mucosal lesions was evaluated using the modified LANZA score (MLS).
Seventy-nine (61.7%) of the regular NSAIDs users and 65 (51.6%) of the on-demand NSAIDs users met our definition of high-risk patients. Adherence in the regular NSAIDs users and on-demand NSAIDs users was 25 (31.7%) and 16 (24.6%), respectively. The incidence of gastric mucosal lesions (MLS ≧ 1) was significantly higher in the nonadherence group than in the adherence group for both regular NSAIDs users (59.3 vs. 28.0%, P = 0.01) and on-demand NSAIDs users (63.3 vs. 25.0%, P = 0.01). Gastric ulcers in the regular NSAIDs users were more frequently observed in the nonadherence group than in the adherence group (29.6 vs. 4.0%, P < 0.01).
Nonadherence was associated with a high prevalence of NSAIDs-induced gastric mucosal lesions.
KeywordsNSAIDs-guideline Gastric mucosal lesions Adherence
- 4.Shiokawa Y, Nobenaga T, Saitoh T, Asaji S, Ogawa A. Epidemiological study on upper digestive injuries by non-steroidal anti-inflammatory drugs. J Jpn Rheum Assoc. 1991;31:96–111 (in Japanese).Google Scholar
- 9.Recommendation for the medical management of osteoarthritis of the hip and knee. 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000;43:1905–15.Google Scholar
- 15.Moens HJ, Van Croonenborg JJ, Al MJ, van den Bemt PM, Lourens J, Numans ME, et al. Guideline: ‘NSAID use and the prevention of gastric damage’. Ned Tijdschr Geneeskd. 2003;148:604–8.Google Scholar
- 18.Lanza FL, Fakouhi D, Rubin A, Davis RE, Rack MF, Nissen C, et al. A double-blind placebo-controlled comparison of the efficacy and safety of 50, 100, and 200 micrograms of misoprostol q.i.d. in the prevention of ibuprofen-induced gastric and duodenal mucosal lesions and symptoms. Am J Gastroenterol. 1989;84:633–6.PubMedGoogle Scholar
- 21.Hawkey C, Talley NJ, Yeomans ND, Jones R, Sung JJ, Langstrom G, et al. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal anti-inflammatory drugs, including selective COX-2 inhibitors. Am J Gastroenterol. 2005;100:1028–36.CrossRefPubMedGoogle Scholar
- 23.Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2002;(4):CD002296.Google Scholar
- 25.Tsumura H, Tamura I, Tanaka H, Chinzei R, Ishida T, Masuda A, et al. Prescription of non steroidal anti-inflammatory drugs and co-prescribed drugs for mucosal protection: analysis of the present status based on questionnaires obtained from orthopedists in Japan. Intern Med. 2007;46:927–31.CrossRefPubMedGoogle Scholar
- 26.EBM ni motozuku ikaiyou shinnryou gaidolain dai2han. NSAID kaiyou yobou. in EBM ni motozuku ikaiyou shinnryou gaidolain. Jihou, 2007 (in Japanese).Google Scholar
- 28.Sorensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Torp-Pedersen C, Gislason GH. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Demark: a retrospective analysis of nationwide registry data. Lancet. 2009;374:1967–74.CrossRefPubMedGoogle Scholar
- 29.Naito Y, Yoshikawa T, Iinuma S, Yagi N, Matsuyama K, Boku Y, et al. Rebamipide protects against indomethacin-induced gastric mucosal injury in healthy volunteers in a double-blind, placebo-controlled study. Dig Dis Sci. 1998;43:83–9.Google Scholar
- 30.Lanza FL, Royer GL, Nelson RS, Chen TT, Sechman CE, Rack MF. A comparative endoscopic evaluation of the damaging effects of nonsteroidal anti-inflammatory agents on the gastric and duodenal mucosa. Am J Gatroenterol. 1981;75:17–21.Google Scholar
- 31.Kobayashi K, Mizushima Y, Yanagawa A, Kasukawa R, Ito J, Koshino T, et al. Prophylactic effects ranitidine, a H2 receptor antagonist, on gastric and duodenal lesions induced by nonsteroidal anti-inflammatory agents. J Adult Dis. 1990;20:253–64 (in Japanese).Google Scholar